ID

31593

Descripción

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00736645

Link

https://clinicaltrials.gov/show/NCT00736645

Palabras clave

Versiones (1)
  1. 10/9/18 10/9/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

10 de septiembre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostate Cancer NCT00736645

Inglés

Eligibility Prostate Cancer NCT00736645

1 formularios  
Criteria
Descripción

Criteria

histologically proven adenocarcinoma of the prostate
Descripción

Adenocarcinoma of prostate

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007112
diagnosed by sextant or greater biopsy
Descripción

Diagnosis Sextant biopsy | Diagnosis Biopsy Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0011900
UMLS CUI [1,2]
C3846092
UMLS CUI [2,1]
C0011900
UMLS CUI [2,2]
C0005558
UMLS CUI [2,3]
C1265611
clinical stage < t3 (stage i or ii) disease
Descripción

Disease TNM clinical staging

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C3258246
prostate-specific antigen < 20.0 ng/ml
Descripción

Prostate specific antigen measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201544
gleason score < 8
Descripción

Gleason score

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3203027
scheduled to undergo prostatectomy or brachytherapy
Descripción

Prostatectomy Scheduled | Brachytherapy Scheduled

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0033573
UMLS CUI [1,2]
C0205539
UMLS CUI [2,1]
C0006098
UMLS CUI [2,2]
C0205539
patient characteristics:
Descripción

Client Characteristics

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0815172
life expectancy > 5 years
Descripción

Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
no other prior malignancy (excluding nonmelanoma skin cancer) in the past 5 years
Descripción

Exclusion | Cancer Other | Exception Skin carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2828389
UMLS CUI [2]
C1707251
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0699893
willing and able to take finasteride, selenomethionine, and/or placebo for 3-5 weeks prior to prostatectomy/brachytherapy
Descripción

Finasteride | Selenomethionine | Placebo

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0060389
UMLS CUI [2]
C0036584
UMLS CUI [3]
C1696465
prior concurrent therapy:
Descripción

Therapeutic procedure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0087111
more than 1 year since prior finasteride, dutasteride, sereona repens (saw palmetto), or any other 5-α reductase inhibitor
Descripción

Finasteride Previous | Dutasteride Previous | Serenoa repens extract Previous | Saw palmetto extract Previous | 5-alpha Reductase Inhibitors Previous

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0060389
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C0754659
UMLS CUI [2,2]
C0205156
UMLS CUI [3,1]
C3491902
UMLS CUI [3,2]
C0205156
UMLS CUI [4,1]
C0771607
UMLS CUI [4,2]
C0205156
UMLS CUI [5,1]
C2936788
UMLS CUI [5,2]
C0205156
no prior hormonal therapy or radiotherapy
Descripción

Exclusion Criteria | Hormone Therapy | Therapeutic radiology procedure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0279025
UMLS CUI [3]
C1522449
more than 30 days since prior and no concurrent participation in any other clinical trial involving a medical, surgical, nutritional, or life-style intervention (e.g., dietary modification or exercise)
Descripción

Exclusion Criteria | Study Subject Participation Status Involving Therapeutic intervention | Study Subject Participation Status Involving Surgical intervention | Study Subject Participation Status Involving Nutritional Intervention | Study Subject Participation Status Involving Life Style Intervention | Dietary Modification | Exercise

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C2348568
UMLS CUI [2,2]
C1314939
UMLS CUI [2,3]
C0087111
UMLS CUI [3,1]
C2348568
UMLS CUI [3,2]
C1314939
UMLS CUI [3,3]
C0549433
UMLS CUI [4,1]
C2348568
UMLS CUI [4,2]
C1314939
UMLS CUI [4,3]
C1882127
UMLS CUI [5,1]
C2348568
UMLS CUI [5,2]
C1314939
UMLS CUI [5,3]
C0023676
UMLS CUI [5,4]
C0184661
UMLS CUI [6]
C0086153
UMLS CUI [7]
C0015259
no concurrent selenium dietary supplement at doses > 200 mg/day, including multivitamin supplements
Descripción

Exclusion Criteria | Selenium supplement Dose U/day | Multivitamin Supplements

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C0521939
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0456683
UMLS CUI [3,1]
C0301532
UMLS CUI [3,2]
C0242295
at least 30 days since > 200mg/day of prior selenium dietary supplement
Descripción

Selenium supplement Previous U/day

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0521939
UMLS CUI [1,2]
C0205156
UMLS CUI [1,3]
C0456683
no other concurrent hormonal therapy, including 5-α reductase inhibitors (e.g., finasteride or dutasteride); anti-androgens (e.g., bicalutamide, flutamide, or ketoconazole); or luteinizing hormone-releasing hormone agonists (e.g., leuprolide acetate, goserelin acetate, or abarelix)
Descripción

Exclusion Criteria | Hormone Therapy | 5-alpha Reductase Inhibitors | Finasteride | Dutasteride | Androgen Antagonists | bicalutamide | Flutamide | Ketoconazole | Luteinizing Hormone-releasing Hormone Agonist | Leuprolide Acetate | Goserelin Acetate | abarelix

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0279025
UMLS CUI [3]
C2936788
UMLS CUI [4]
C0060389
UMLS CUI [5]
C0754659
UMLS CUI [6]
C0002842
UMLS CUI [7]
C0285590
UMLS CUI [8]
C0016384
UMLS CUI [9]
C0022625
UMLS CUI [10]
C1518041
UMLS CUI [11]
C0700596
UMLS CUI [12]
C0700476
UMLS CUI [13]
C0965390
Volver a la parte superior de la página

Similar models

Eligibility Prostate Cancer NCT00736645

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Adenocarcinoma of prostate
Item
histologically proven adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Diagnosis Sextant biopsy | Diagnosis Biopsy Quantity
Item
diagnosed by sextant or greater biopsy
boolean
C0011900 (UMLS CUI [1,1])
C3846092 (UMLS CUI [1,2])
C0011900 (UMLS CUI [2,1])
C0005558 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Disease TNM clinical staging
Item
clinical stage < t3 (stage i or ii) disease
boolean
C0012634 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Prostate specific antigen measurement
Item
prostate-specific antigen < 20.0 ng/ml
boolean
C0201544 (UMLS CUI [1])
Gleason score
Item
gleason score < 8
boolean
C3203027 (UMLS CUI [1])
Prostatectomy Scheduled | Brachytherapy Scheduled
Item
scheduled to undergo prostatectomy or brachytherapy
boolean
C0033573 (UMLS CUI [1,1])
C0205539 (UMLS CUI [1,2])
C0006098 (UMLS CUI [2,1])
C0205539 (UMLS CUI [2,2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Life Expectancy
Item
life expectancy > 5 years
boolean
C0023671 (UMLS CUI [1])
Exclusion | Cancer Other | Exception Skin carcinoma
Item
no other prior malignancy (excluding nonmelanoma skin cancer) in the past 5 years
boolean
C2828389 (UMLS CUI [1])
C1707251 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0699893 (UMLS CUI [3,2])
Finasteride | Selenomethionine | Placebo
Item
willing and able to take finasteride, selenomethionine, and/or placebo for 3-5 weeks prior to prostatectomy/brachytherapy
boolean
C0060389 (UMLS CUI [1])
C0036584 (UMLS CUI [2])
C1696465 (UMLS CUI [3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
Finasteride Previous | Dutasteride Previous | Serenoa repens extract Previous | Saw palmetto extract Previous | 5-alpha Reductase Inhibitors Previous
Item
more than 1 year since prior finasteride, dutasteride, sereona repens (saw palmetto), or any other 5-α reductase inhibitor
boolean
C0060389 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0754659 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C3491902 (UMLS CUI [3,1])
C0205156 (UMLS CUI [3,2])
C0771607 (UMLS CUI [4,1])
C0205156 (UMLS CUI [4,2])
C2936788 (UMLS CUI [5,1])
C0205156 (UMLS CUI [5,2])
Exclusion Criteria | Hormone Therapy | Therapeutic radiology procedure
Item
no prior hormonal therapy or radiotherapy
boolean
C0680251 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
Exclusion Criteria | Study Subject Participation Status Involving Therapeutic intervention | Study Subject Participation Status Involving Surgical intervention | Study Subject Participation Status Involving Nutritional Intervention | Study Subject Participation Status Involving Life Style Intervention | Dietary Modification | Exercise
Item
more than 30 days since prior and no concurrent participation in any other clinical trial involving a medical, surgical, nutritional, or life-style intervention (e.g., dietary modification or exercise)
boolean
C0680251 (UMLS CUI [1])
C2348568 (UMLS CUI [2,1])
C1314939 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C2348568 (UMLS CUI [3,1])
C1314939 (UMLS CUI [3,2])
C0549433 (UMLS CUI [3,3])
C2348568 (UMLS CUI [4,1])
C1314939 (UMLS CUI [4,2])
C1882127 (UMLS CUI [4,3])
C2348568 (UMLS CUI [5,1])
C1314939 (UMLS CUI [5,2])
C0023676 (UMLS CUI [5,3])
C0184661 (UMLS CUI [5,4])
C0086153 (UMLS CUI [6])
C0015259 (UMLS CUI [7])
Exclusion Criteria | Selenium supplement Dose U/day | Multivitamin Supplements
Item
no concurrent selenium dietary supplement at doses > 200 mg/day, including multivitamin supplements
boolean
C0680251 (UMLS CUI [1])
C0521939 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0301532 (UMLS CUI [3,1])
C0242295 (UMLS CUI [3,2])
Selenium supplement Previous U/day
Item
at least 30 days since > 200mg/day of prior selenium dietary supplement
boolean
C0521939 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
Exclusion Criteria | Hormone Therapy | 5-alpha Reductase Inhibitors | Finasteride | Dutasteride | Androgen Antagonists | bicalutamide | Flutamide | Ketoconazole | Luteinizing Hormone-releasing Hormone Agonist | Leuprolide Acetate | Goserelin Acetate | abarelix
Item
no other concurrent hormonal therapy, including 5-α reductase inhibitors (e.g., finasteride or dutasteride); anti-androgens (e.g., bicalutamide, flutamide, or ketoconazole); or luteinizing hormone-releasing hormone agonists (e.g., leuprolide acetate, goserelin acetate, or abarelix)
boolean
C0680251 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
C2936788 (UMLS CUI [3])
C0060389 (UMLS CUI [4])
C0754659 (UMLS CUI [5])
C0002842 (UMLS CUI [6])
C0285590 (UMLS CUI [7])
C0016384 (UMLS CUI [8])
C0022625 (UMLS CUI [9])
C1518041 (UMLS CUI [10])
C0700596 (UMLS CUI [11])
C0700476 (UMLS CUI [12])
C0965390 (UMLS CUI [13])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial